Roche (RHHBY) expects an increase in Group sales in the mid single digit range CER for 2026. Core earnings per share are targeted to develop in the high single digit range CER. Roche expects to further increase its dividend in Swiss francs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Genentech’s treatment of KRAS G12C-positive NSCLC granted FDA orphan designation
- Genetech says Phase III METEROID study of Enspryng meets primary endpoint
- Roche announces U.S. FDA accepted sBLA for Gazyva/Gazyvaro
- Roche’s Genentech reports FDA approval of sBLA for Gazyva
- Trump names Erica Schwartz CDC Director